Phaseline

Companies › Alkermes

Alkermes: clinical trials, targets and expected readouts

3 active drug programs in 8 registered trials: 4 Phase 2, 4 Phase 3; Psychiatry, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALKS 2680
Hypocretin/orexin pathway modulator
HCRTPhase 3Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic HypersomniaNov 2026
Samidorphan
Mu opioid receptor antagonist; Kappa opioid receptor partial agonist; Delta opioid receptor partial agonist
OPRM1, OPRK1, OPRD1Phase 3Schizophrenia–
ALKS 7290
NMDA receptor antagonist
–Phase 2Attention Deficit Disorder With Hyperactivity (ADHD); Major Depressive Disorder (MDD)Jul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05303064SamidorphanPhase 3SchizophreniaPsychiatrySep 2026
NCT06843590ALKS 2680Phase 2Idiopathic HypersomniaNeurologyNov 2026
NCT07455383ALKS 2680Phase 3Narcolepsy Type 1NeurologyMay 2027
NCT07502443ALKS 2680Phase 3Narcolepsy Type 2NeurologyMay 2027
NCT07540897ALKS 2680Phase 3Narcolepsy Type 1NeurologyJun 2027
NCT07755410ALKS 7290Phase 2Attention Deficit Disorder With Hyperactivity (ADHD)PsychiatryJul 2027
NCT07901179ALKS 7290Phase 2Major Depressive Disorder (MDD)PsychiatryJan 2028
NCT06767683ALKS 2680Phase 2Narcolepsy Type 1NeurologyJun 2030

From the company's SEC filings

Cash and short-term investments of $755m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

HCRT (1) OPRM1 (1) OPRK1 (1) OPRD1 (1)

Companies with the same targets

Trevi Therapeutics Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Adneuris Therapeutics Boulder Care Inventage Lab. Takeda Centessa Pharmaceuticals (UK)

Companies built like this

Neurocrine Biosciences Supernus Pharmaceuticals Definium Therapeutics US Intra-Cellular Therapies ACADIA Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.